Compare INLX & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INLX | CVM |
|---|---|---|
| Founded | 1996 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.5M | 41.2M |
| IPO Year | N/A | 1987 |
| Metric | INLX | CVM |
|---|---|---|
| Price | $8.18 | $4.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.2K | ★ 75.7K |
| Earning Date | 03-23-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,539,674.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.50 | $1.98 |
| 52 Week High | $15.72 | $20.41 |
| Indicator | INLX | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 50.69 | 41.61 |
| Support Level | $8.00 | $4.60 |
| Resistance Level | $8.51 | $5.20 |
| Average True Range (ATR) | 0.09 | 0.50 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 45.90 | 8.20 |
Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Document Management and Document Conversion. The Document Management segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Conversion offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Conversion Segment.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.